Related Experiment Video
Updated: Aug 27, 2025
08:09
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
7.6K
Gut-oriented disease modifying therapy for Parkinson's disease.
Chin-Hsien Lin1, Hsin-Chih Lai2, Ming-Shiang Wu3
1Department of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan; Institute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|October 1, 2022
Summary
Parkinson's disease (PD) may originate in the gut, affecting the gut-brain axis. Targeting gut microbiota offers a promising avenue for novel disease-modifying therapies for PD.
Area of Science:
- Neuroscience
- Gastroenterology
- Microbiology
Background:
- Parkinson's disease (PD) is a common neurodegenerative disorder.
- Neuropathology suggests PD may initiate in the gut enteric nervous system, impacting the gut-brain axis.
- Current PD treatments offer symptomatic relief but lack disease-modifying capabilities.
Purpose of the Study:
- To review the multifaceted roles of gut microbiota in the gut-brain axis of PD.
- To explore the potential of targeting gut microbiota for disease modification in Parkinson's disease.
Main Methods:
- Review of current scientific literature.
- Analysis of metagenomic sequencing and metabolomic data in PD patients.
- Examination of the gut-brain axis in PD pathogenesis.
Main Results:
- Significant differences in gut microbiome composition and metabolites exist between PD patients and controls.
- Gut microenvironmental changes are implicated in early PD pathogenesis.
- Gut microbiota play multifunctional roles in the gut-brain axis relevant to PD.
Conclusions:
- The gut microbiome is a critical factor in Parkinson's disease development and progression.
- Interventions targeting the gut microenvironment may benefit PD patients, particularly those with gut-initiated disease.
- Targeting gut microbiota represents a novel therapeutic strategy for potential disease modification in Parkinson's disease.
Related Concept Videos
01:24Parkinson's Disease: Treatment
354
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
354
01:15Parkinson's Disease: Overview
672
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
672
01:22Alzheimer's Disease: Treatment
248
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
248
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
250
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
250
01:29Inflammatory Bowel Disease IV: Pharmacological Management
173
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
173
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
418
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
418